The stock of Mereo Biopharma Group Plc ADR (MREO) has gone up by 8.20% for the week, with a 14.14% rise in the past month and a -10.13% drop in the past quarter. The volatility ratio for the week is 5.92%, and the volatility levels for the past 30 days are 9.69% for MREO. The simple moving average for the past 20 days is 20.10% for MREO’s stock, with a -22.25% simple moving average for the past 200 days.
Is It Worth Investing in Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Right Now?
Company’s 36-month beta value is 0.51.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MREO is 139.69M, and currently, short sellers hold a 4.72% ratio of that floaft. The average trading volume of MREO on May 02, 2025 was 1.47M shares.
MREO) stock’s latest price update
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) has experienced a rise in its stock price by 4.04 compared to its previous closing price of 2.60. However, the company has seen a gain of 8.20% in its stock price over the last five trading days. globenewswire.com reported 2025-03-26 that Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025
Analysts’ Opinion of MREO
Many brokerage firms have already submitted their reports for MREO stocks, with JP Morgan repeating the rating for MREO by listing it as a “Overweight.” The predicted price for MREO in the upcoming period, according to JP Morgan is $7 based on the research report published on March 27, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see MREO reach a price target of $7. The rating they have provided for MREO stocks is “Buy” according to the report published on December 06th, 2024.
Robert W. Baird gave a rating of “Outperform” to MREO, setting the target price at $8 in the report published on June 13th of the previous year.
MREO Trading at 13.69% from the 50-Day Moving Average
After a stumble in the market that brought MREO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.12% of loss for the given period.
Volatility was left at 9.69%, however, over the last 30 days, the volatility rate increased by 5.92%, as shares surge +23.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.05% lower at present.
During the last 5 trading sessions, MREO rose by +9.00%, in comparison to the 20-day moving average, which settled at $2.25. In addition, Mereo Biopharma Group Plc ADR saw -22.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MREO starting from Scots-Knight Denise, who sale 60,046 shares at the price of $4.22 back on Sep 13 ’24. After this action, Scots-Knight Denise now owns 808,921 shares of Mereo Biopharma Group Plc ADR, valued at $253,454 using the latest closing price.
Scots-Knight Denise, the Chief Executive Officer of Mereo Biopharma Group Plc ADR, sale 28,611 shares at $4.47 during a trade that took place back on Sep 12 ’24, which means that Scots-Knight Denise is holding 868,967 shares at $127,968 based on the most recent closing price.
Stock Fundamentals for MREO
The total capital return value is set at -0.76.
Based on Mereo Biopharma Group Plc ADR (MREO), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -5.11. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -34.6.
Currently, EBITDA for the company is -47.36 million with net debt to EBITDA at 1.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.40.
Conclusion
In a nutshell, Mereo Biopharma Group Plc ADR (MREO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
